PMID- 33885242
OWN - NLM
STAT- MEDLINE
DCOM- 20210920
LR  - 20230919
IS  - 1581-3207 (Electronic)
IS  - 1318-2099 (Print)
IS  - 1318-2099 (Linking)
VI  - 55
IP  - 1
DP  - 2020 Dec 3
TI  - Postoperative radiotherapy for patients with completely resected pathological 
      stage IIIA-N2 non-small cell lung cancer: a preferential benefit for squamous 
      cell carcinoma.
PG  - 66-76
LID - 10.2478/raon-2020-0070 [doi]
AB  - BACKGROUND: The beneficial effect of postoperative radiotherapy (PORT) on 
      completely resected pathological IIIA-N2 (pIIIA-N2) non-small cell lung cancer 
      (NSCLC) has been a subject of interest with controversy. The aim of the study was 
      to distinguish the clinical efficacy of PORT on lung adenocarcinoma (LADC) and 
      lung squamous cell carcinoma (LSCC) among pIIIA-N2 NSCLC. PATIENTS AND METHODS: 
      Between October 2010 and September 2016, 288 consecutive patients with completely 
      resected pIIIA-N2 NSCLC at Beijing Chest Hospital were retrospectively analyzed, 
      which consisted of 194 cases of LADC and 85 cases of LSCC. There were 42 (21.6%) 
      patients treated with PORT in LADC cases and 19 (22.3%) patients treated with 
      PORT in LSCC cases. The 5-year overall survival (OS), loco-regional 
      recurrence-free survival (LRFS), distant metastasis-free survival (DMFS) were 
      calculated using the Kaplan-Meier method. The prognostic factors were determined 
      using Cox's regression model. RESULTS: Among 194 cases of LADC, the 1-, 3-, and 
      5-year OS in the PORT group were 95.2%, 61.9% and 40.0%, respectively, while in 
      the non-PORT group were 90.1%, 63.3% and 45.0% (p = 0.948). The use of 
      postoperative chemotherapy (POCT) and smoking index >/= 400 were both prognostic 
      factors of 5-year rates of OS, LRFS and DMFS. On the other hand, among 85 cases 
      of LSCC, the 1-, 3-, and 5-year OS in the PORT group were 94.7%, 63.2% and 63.2%, 
      respectively, whereas in the non-PORT group were 86.4%, 48.5% and 37.1% (p = 
      0.026). In this group, only the use of PORT was a favorable prognostic factor for 
      5-year OS, LRFS and DMFS. CONCLUSIONS: Due to clinicopathological differences 
      among completely resected pIIIA-N2 NSCLC, PORT may not be suitable to all 
      patients. Our study distinguishes pIIIA-N2 LSCC from LADC by their positive 
      responses to PORT.
CI  - (c) 2021 Cuimeng Tian, Guimei Liu, Yongxiang Xu, Guangrong Xia, Tongmei Zhang, 
      Jiaqiang Huang, Hui Jiang, Ji Ming Wang, Baolan Li, published by Sciendo.
FAU - Tian, Cuimeng
AU  - Tian C
AD  - Department of Radiation Oncology, Beijing Tuberculosis and Thoracic Tumor 
      Research Institute / Beijing Chest Hospital, Capital Medical University, Beijing, 
      China.
AD  - Laboratory of Cancer ImmunoMetabolism, Center for Cancer Research, National 
      Cancer Institute at Frederick, Frederick, USA.
FAU - Liu, Guimei
AU  - Liu G
AD  - Department of Radiation Oncology, Beijing Tuberculosis and Thoracic Tumor 
      Research Institute / Beijing Chest Hospital, Capital Medical University, Beijing, 
      China.
FAU - Xu, Yongxiang
AU  - Xu Y
AD  - Department of Radiation Oncology, Beijing Tuberculosis and Thoracic Tumor 
      Research Institute / Beijing Chest Hospital, Capital Medical University, Beijing, 
      China.
FAU - Xia, Guangrong
AU  - Xia G
AD  - Department of Radiation Oncology, Beijing Tuberculosis and Thoracic Tumor 
      Research Institute / Beijing Chest Hospital, Capital Medical University, Beijing, 
      China.
FAU - Zhang, Tongmei
AU  - Zhang T
AD  - Department of General Medicine, Beijing Tuberculosis and Thoracic Tumor Research 
      Institute / Beijing Chest Hospital, Capital Medical University, Beijing, China.
FAU - Huang, Jiaqiang
AU  - Huang J
AD  - Department of Cellular and Molecular Biology, Beijing Tuberculosis and Thoracic 
      Tumor Research Institute / Beijing Chest Hospital, Capital Medical University, 
      Beijing, China.
FAU - Jiang, Hui
AU  - Jiang H
AD  - Division of Technology, Beijing Tuberculosis and Thoracic Tumor Research 
      Institute / Beijing Chest Hospital, Capital Medical University, Beijing, China.
FAU - Ming Wang, Ji
AU  - Ming Wang J
AD  - Laboratory of Cancer ImmunoMetabolism, Center for Cancer Research, National 
      Cancer Institute at Frederick, Frederick, USA.
FAU - Li, Baolan
AU  - Li B
AD  - Department of General Medicine, Beijing Tuberculosis and Thoracic Tumor Research 
      Institute / Beijing Chest Hospital, Capital Medical University, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, N.I.H., Intramural
PT  - Research Support, Non-U.S. Gov't
DEP - 20201203
PL  - Poland
TA  - Radiol Oncol
JT  - Radiology and oncology
JID - 9317213
SB  - IM
MH  - Carcinoma, Non-Small-Cell Lung/pathology/*radiotherapy/surgery
MH  - Carcinoma, Squamous Cell/pathology/*radiotherapy/surgery
MH  - Female
MH  - Humans
MH  - Lung Neoplasms/pathology/*radiotherapy/surgery
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Radiotherapy, Adjuvant
MH  - Retrospective Studies
MH  - Risk Factors
MH  - Survival Analysis
PMC - PMC7877270
OTO - NOTNLM
OT  - lung adenocarcinoma
OT  - lung squamous cell carcinoma
OT  - pIIIA-N2
OT  - postoperative radiotherapy
COIS- Conflict of interest No potential conflicts of interest were disclosed.
EDAT- 2021/04/23 06:00
MHDA- 2021/09/21 06:00
PMCR- 2021/03/01
CRDT- 2021/04/22 08:50
PHST- 2020/07/21 00:00 [received]
PHST- 2020/10/06 00:00 [accepted]
PHST- 2021/04/22 08:50 [entrez]
PHST- 2021/04/23 06:00 [pubmed]
PHST- 2021/09/21 06:00 [medline]
PHST- 2021/03/01 00:00 [pmc-release]
AID - raon-2020-0070 [pii]
AID - 10.2478/raon-2020-0070 [doi]
PST - epublish
SO  - Radiol Oncol. 2020 Dec 3;55(1):66-76. doi: 10.2478/raon-2020-0070.